BTIG analyst Mark Massaro reiterated a Buy rating on Exact Sciences (EXAS – Research Report) yesterday and set a price target of $65.00. The company’s shares closed yesterday at $45.18.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Massaro is an analyst with an average return of -7.9% and a 28.98% success rate. Massaro covers the Healthcare sector, focusing on stocks such as NeoGenomics, Zoetis, and Natera.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Exact Sciences with a $70.38 average price target, implying a 55.78% upside from current levels. In a report released on March 11, Wells Fargo also maintained a Buy rating on the stock with a $63.00 price target.
The company has a one-year high of $79.62 and a one-year low of $40.62. Currently, Exact Sciences has an average volume of 2.2M.
Read More on EXAS:
- Exact Sciences initiated with a Sector Perform at RBC Capital
- Exact Sciences: Promising Growth with Cologuard Plus and New Product Launches
- Exact Sciences price target lowered to $70 from $75 at Piper Sandler
- Exact Sciences price target raised to $73 from $70 at Scotiabank
- Exact Sciences Corp Earnings Call Highlights Growth